Conference Track

HIV Management in Developed Countries

Source: CCO Official Conference Coverage of the 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention

Capsule Summaries

VA Cohort: Nonsignificant Association of Abacavir Exposure With Acute MI, Further Reduced by Controlling for Chronic Kidney Disease
BICOMBO Substudy: Abacavir- and Tenofovir-Based HAART Do Not Affect Biological Mechanisms Associated With Cardiovascular Dysfunction
GRACE Study: Safety and Efficacy of Darunavir/Ritonavir Similar in Treatment-Experienced Women vs Men
FOTO Study: 5-Days-On, 2-Days-Off Dosing Strategy Appears Comparable to Continuous HAART in Patients With Virologic Suppression on Efavirenz, Tenofovir, and Emtricitabine
Raltegravir Plus Unboosted Atazanavir Associated With Low Rate of Virologic Failure Through 24 Weeks in Treatment-Experienced Patients
ESPRIT/SILCAAT: At Comparable CD4+ Cell Counts, Risk of Opportunistic Disease or Death Increased With Addition of IL-2 to HAART vs HAART Alone
STALWART: Patients Treated With IL-2 Less Likely to Initiate Continuous Antiretroviral Therapy, Have Increased Risk of Morbidity and Mortality
MERIT-ES: 96-Week Efficacy of Maraviroc Similar to That of Efavirenz in Treatment-Naive Patients With R5 Tropism
M06-802: Similar Safety, Efficacy of Lopinavir/Ritonavir Dosed Once Daily vs Twice Daily in Therapy-Experienced Patients at 48 Weeks
Novel Integrase Inhibitor, S/GSK1349572, Demonstrates Potent Virologic Suppression in 10-Day Monotherapy Trial
MONET: Efficacy of Switch to Darunavir/Ritonavir Monotherapy Noninferior to Darunavir/Ritonavir Plus NRTIs in Patients Receiving Stable, Suppressive HAART
Quebec Case-Control Study Suggests Association Between Exposure to Specific NRTIs and PIs and Risk of AMI
High Prevalence of Vitamin D Deficiency in UK Cohort, Independently Associated With Race, Low CD4+ Cell Count Nadir, and Efavirenz Use
Substudy Finds No Antiretroviral Class Effect on Long-term Changes in Bone Mineral Density
MONOI (ANRS 136): In Virologically Suppressed Patients, Switch to Darunavir/Ritonavir Noninferior to Continued Darunavir/Ritonavir Plus NRTIs at Week 48 in per Protocol Analysis
ARIES: In Patients With Virologic Suppression on First-line Atazanavir/Ritonavir Plus Abacavir/Lamivudine, Switching to Unboosted Atazanavir Noninferior to Continuing Boosted Regimen

Expert Analysis

From Podium to Practice: HIV Management in Developed Countries

Faculty:

Andrew Carr, MBBS, MD, FRACP
Anton L. Pozniak, MD, FRCP
Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the latest clinical findings on potential associations between use of antiretroviral agents and cardiovascular disease risk
Describe recent data on the relative efficacy of antiretroviral therapy in treatment-experienced women vs men
Discuss new results from clinical trials investigating drug class-sparing regimens and other treatment simplification strategies
Cite the most recent data on the safety and efficacy of new antiretroviral agents
Articulate new findings from studies evaluating prevalence and risk factors for bone mineral density loss and vitamin D deficiency among HIV-infected patients

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: October 09, 2009

Expiration Date: October 08, 2010

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.